Sorafenib Improves Survival in Metastatic Hepatocellular Carcinoma: A Case Report

Hepatocellular carcinoma (HCC) is a very common cancer. Curative treatments and local ones are well validated. Sorafenib, a multi-kinase receptor inhibitor was introduced in 2007 for advanced HCC in patients with preserved liver function. HCC is known to be resistant to systemic chemotherapy, and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Nery, Filipe, Graca, Luis, Ribeiro, Manuel, Guimaraes, Henrique, Miranda, Helena Pessegueiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2010
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649801/
https://www.ncbi.nlm.nih.gov/pubmed/29147210
http://dx.doi.org/10.4021/wjon240w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649801/
https://www.ncbi.nlm.nih.gov/pubmed/29147210
http://dx.doi.org/10.4021/wjon240w

Ejemplares similares